Biotech Bid Up Following First Patient Dosage
January 11 2023 - 9:25AM
AllPennyStocks.com
A Boston-based biotech company is turning
heads on Wednesday after the company announced that the first
patient was dosed in its Phase 1/2a monotherapy clinical trial of
ATRN-119,...
To read the full story on AllPennyStocks.com, click
here.
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Dec 2024 to Jan 2025
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jan 2024 to Jan 2025